Contribute Try STAT+ Today

WASHINGTON — Sen. Chuck Grassley on Monday accused Democrats of walking away from negotiations on a bill meant to lower prescription drug prices — a bill that has, until now, enjoyed more support from Democrats in the Senate than from most Republicans in the chamber.

The Iowa Republican’s surprisingly public airing of grievances, in a Wall Street Journal op-ed, is the latest indication that Congress is unlikely to pass meaningful pharmaceutical industry reforms before November’s election.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Looks to me as though PCMA got to both parties. It’s amazing how a little gelt
    makes nothing happen.

Comments are closed.